Breaking News Instant updates and real-time market news.

MDGL

Madrigal Pharmaceuticals

$246.59

-4.69 (-1.87%)

07:40
08/07/18
08/07
07:40
08/07/18
07:40

Madrigal sees 'high likelihood of success' for Phase 3 MGL-3196 study

"We believe the 36-week data from our recently completed Phase 2 clinical study of MGL-3196 in patients with NASH suggest a high likelihood of success in a similarly designed Phase 3 study, for which we are actively preparing, pending regulatory agreement," stated Paul Friedman, CEO of Madrigal Pharmaceuticals in this morning's earnings release. "With our financial raise completed, which provided more than $300 million of additional capital, we are in a strong position to expedite the MGL-3196 development program in NASH and dyslipidemias." Added Becky Taub, CMO and Executive VP, Research & Development, "We believe the totality of data from our clinical and preclinical studies to date, including the consistency of the various parameters related to clinical benefits and safety, demonstrate the potential of MGL-3196 to resolve NASH and improve multiple atherogenic lipids. We are pleased our abstract was selected by AASLD as an oral presentation in the presidential plenary clinical session and look forward to presenting these encouraging clinical outcomes in November at The Liver Meeting 2018."

MDGL Madrigal Pharmaceuticals
$246.59

-4.69 (-1.87%)

06/28/18
RAJA
06/28/18
INITIATION
RAJA
Market Perform
Madrigal Pharmaceuticals initiated with a Market Perform at Raymond James
07/12/18
CANT
07/12/18
INITIATION
Target $59
CANT
Overweight
Cantor puts $59 price target on 'undervalued' NASH play Galmed
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Galmed Pharmaceuticals (GLMD) with an Overweight rating and $59 price target. The stock closed yesterday down 45c to $10.55. The company is developing Aramchol, a novel, once-daily, oral therapy to treat liver diseases using fattyacid/bile-acid conjugates, Piros tells investors in a research note. The analyst believes that by Q4 of 2019, only three meaningful non-alcoholic steatohepatitis pivotal programs will be in development: Allergan's (AGN) cenicriviroc, Madrigal Pharmaceuticals' (MDGL) MGL-3196, and Galmed's Aramchol. Of the three drugs, Galmed's has the highest likelihood of achieving improvement on NASH resolution without worsening of fibrosis, and improvement in fibrosis score without worsening of NASH, Piros argues. He believes Galmed is undervalued relative to peers in the NASH space.
08/06/18
GSCO
08/06/18
DOWNGRADE
Target $314
GSCO
Neutral
Madrigal Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Madrigal Pharmaceuticals to Neutral with an unchanged price target of $314. The stock closed Friday down 41c to $250.93. The analyst continues to view MGL-3196 as a "best-in-industry, next-generation drug" for nonalcoholic steatohepatitis. However, with the stock up 173% year-to-date, he believes Madrigal is entering a "period of limited value-driving catalysts." Richter, while admitting a buyout could occur, sees limited upside in the shares.
08/06/18
GSCO
08/06/18
UPGRADE
Target $157
GSCO
Buy
Intercept upgraded to Buy from Sell at Goldman Sachs
Goldman Sachs analyst Salveen Richter double upgraded Intercept Pharmaceuticals (ICPT) to Buy from Sell and raised his price target for the shares to $157 from $46. The stock closed Friday down 3.5%, or $3.57, to $97.26. The analyst says Ocaliva in fatty liver disease nonalcoholic steatohepatitis is the crux of Intercept's value proposition and that he's positive into the Phase 3 Regenerate interim readout in the first half of 2019. Richter this morning also downgraded Madrigal Pharmaceuticals (MDGL) to Neutral from Buy. He believes, however, that Madrigal's MGL-3196 is a "best-in-industry, next-generation" drug for nonalcoholic steatohepatitis. The analyst expects Intercept's Ocaliva will achieve one or both of the Phase 3 co-primary endpoints of NASH resolution and fibrosis improvement. He sees share upside of 60%-plus as the first half of 2019 catalyst approaches. Intercept should benefit from Ocaliva's global first-mover advantage in NASH, Richter tells investors in a research note. Goldman estimates peak global sales of NASH drugs to be $3.7B.

TODAY'S FREE FLY STORIES

CVE

Cenovus Energy

$8.51

-0.185 (-2.13%)

13:05
11/13/18
11/13
13:05
11/13/18
13:05
Options
Cenovus Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFY

Infosys

$9.39

0.06 (0.64%)

12:58
11/13/18
11/13
12:58
11/13/18
12:58
Hot Stocks
Infosys to open technology and innovation hub in Texas, hire 500 workers by 2020 »

Infosys announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

SNE

Sony

$51.64

0.09 (0.17%)

, MSFT

Microsoft

$107.45

0.56 (0.52%)

12:56
11/13/18
11/13
12:56
11/13/18
12:56
OnTheFly
Game On: Take-Two says 'Red Dead 2' has outsold first 'RDR' in just eight days »

Welcome to "Game On," The…

SNE

Sony

$51.64

0.09 (0.17%)

MSFT

Microsoft

$107.45

0.56 (0.52%)

T

AT&T

$30.63

-0.17 (-0.55%)

NTDOY

Nintendo

$0.00

(0.00%)

ATVI

Activision Blizzard

$52.93

-0.97 (-1.80%)

TTWO

Take-Two

$108.52

-0.51 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 28

    Nov

  • 03

    Mar

VOYA

Voya Financial

$46.38

1.795 (4.03%)

12:55
11/13/18
11/13
12:55
11/13/18
12:55
Hot Stocks
Breaking Hot Stocks news story on Voya Financial »

Voya Financial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

M

Macy's

$36.27

-0.77 (-2.08%)

, APRN

Blue Apron

$1.17

-0.08 (-6.40%)

12:47
11/13/18
11/13
12:47
11/13/18
12:47
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

M

Macy's

$36.27

-0.77 (-2.08%)

APRN

Blue Apron

$1.17

-0.08 (-6.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 28

    Nov

WIX

Wix.com

$91.01

2.54 (2.87%)

, REZI

Resideo

$21.90

0.56 (2.62%)

12:47
11/13/18
11/13
12:47
11/13/18
12:47
Earnings
Notable companies reporting after market close »

Notable companies…

WIX

Wix.com

$91.01

2.54 (2.87%)

REZI

Resideo

$21.90

0.56 (2.62%)

SWCH

Switch

$9.16

-0.18 (-1.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

SIRI

Sirius XM

$6.26

0.15 (2.46%)

12:47
11/13/18
11/13
12:47
11/13/18
12:47
Conference/Events
Sirius XM management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

OESX

Orion Energy

$0.80

-0.0501 (-5.89%)

12:44
11/13/18
11/13
12:44
11/13/18
12:44
Recommendations
Orion Energy analyst commentary  »

Orion Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SBUX

Starbucks

$68.05

0.14 (0.21%)

12:41
11/13/18
11/13
12:41
11/13/18
12:41
Periodicals
Starbucks lays off 5%, or 350, corporate employees, Seattle Times reports »

As part of its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MET

MetLife

$46.01

1.29 (2.88%)

12:40
11/13/18
11/13
12:40
11/13/18
12:40
Options
8.2K Metlife Jan 47.5 - 50 call spreads bought for 82c »

8.2K Metlife Jan 47.5 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CKPT

Checkpoint Therapeutics

$2.37

0.19 (8.72%)

12:38
11/13/18
11/13
12:38
11/13/18
12:38
Hot Stocks
Checkpoint Therapeutics director Lindsay Rosenwald buys 100K shares of stock »

Checkpoint Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEAR

Turtle Beach

$15.81

0.56 (3.67%)

12:35
11/13/18
11/13
12:35
11/13/18
12:35
Options
Turtle Beach put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

KORS

Michael Kors

$49.26

1.51 (3.16%)

12:34
11/13/18
11/13
12:34
11/13/18
12:34
Hot Stocks
Michael Kors CEO sees double digit revenue growth in 2020 »

Michael Kors Chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SBUX

Starbucks

$68.02

0.11 (0.16%)

12:32
11/13/18
11/13
12:32
11/13/18
12:32
Periodicals
Starbucks to lay off 5% of corporate workforce, Dow Jones says »

The layoffs, which total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

VOYA

Voya Financial

$46.22

1.635 (3.67%)

12:29
11/13/18
11/13
12:29
11/13/18
12:29
Hot Stocks
Breaking Hot Stocks news story on Voya Financial »

Voya Financial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

NIO

NIO Inc.

$6.77

0.12 (1.80%)

12:25
11/13/18
11/13
12:25
11/13/18
12:25
Options
NIO Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
11/13/18
11/13
12:25
11/13/18
12:25
Conference/Events
William Blair specialty finance analyst holds a group luncheon »

Specialty Finance Analyst…

DVMT

Dell Technologies

$103.00

4.58 (4.65%)

, VMW

VMware

$151.32

3.16 (2.13%)

12:24
11/13/18
11/13
12:24
11/13/18
12:24
Periodicals
Dell considering raising bid for DVMT tracking stock, Reuters says »

Dell Technologies (DVMT)…

DVMT

Dell Technologies

$103.00

4.58 (4.65%)

VMW

VMware

$151.32

3.16 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 11

    Dec

AKRX

Akorn

$6.74

0.02 (0.30%)

, TEVA

Teva

$23.78

0.09 (0.38%)

12:18
11/13/18
11/13
12:18
11/13/18
12:18
Periodicals
Court rules Allergan's patents on Restasis are invalid, Bloomberg reports »

The U.S. Court of Appeals…

AKRX

Akorn

$6.74

0.02 (0.30%)

TEVA

Teva

$23.78

0.09 (0.38%)

AGN

Allergan

$163.97

0.15 (0.09%)

MYL

Mylan

$36.19

0.25 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 15

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/13/18
11/13
12:17
11/13/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$274.51

1.92 (0.70%)

, SPX

S&P 500

$0.00

(0.00%)

12:16
11/13/18
11/13
12:16
11/13/18
12:16
Periodicals
John Kelly may soon depart Trump administration, NBC News reports »

Chief of Staff John Kelly…

SPY

SPDR S&P 500 ETF Trust

$274.51

1.92 (0.70%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/13/18
11/13
12:16
11/13/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETSY

Etsy

$47.77

-2.87 (-5.67%)

12:15
11/13/18
11/13
12:15
11/13/18
12:15
Options
Etsy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$274.18

1.59 (0.58%)

12:13
11/13/18
11/13
12:13
11/13/18
12:13
General news
Trump says New York Times story on North Korea missile bases 'inaccurate' »

President Donald Trump…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$274.18

1.59 (0.58%)

NYT

New York Times

$26.21

-0.135 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$13.58

0.33 (2.49%)

12:11
11/13/18
11/13
12:11
11/13/18
12:11
Hot Stocks
Breaking Hot Stocks news story on Summit Materials »

Southeastern Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.